Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody.

Somasundaram, Rajasekharan; Žaloudík, Jan; Jacob, L.; Benden, Andrea; Sperlagh, Melinda; Hart, E.; Marks, Geoffrey C.; Kane, Melissa; Mastrangelo, Michael J.; Herlyn, Dorothee

doi:10.4049/jimmunol.155.6.3253

Cited by 60 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D. Herlyn (Philadelphia, Pa.) introduced this concept (Herlyn et al, 1996). Anti-idiotypic antibodies functionally mimic protein or carbohydrate epitopes of tumor antigens and induce humoral, cellular, and protective immunity in animals and cancer patients (Herlyn et al, 1994;Somasundaram et al, 1995). N.-K. Cheung (New York, N.Y.) presented his data using the anti-GD2 monoclonal antibody 3F8, both as a radioimmunotherapy agent and as an inducer of an idiotypic network (Cheung et al, 1994a(Cheung et al, , 1994b.…”

Section: Antibody-based Vaccine Strategiesmentioning

confidence: 99%

THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif.

Sampson

1999

Neuro-Oncology

View full text Add to dashboard Cite

the issues surrounding the development of a vaccine therapy for MPBT. 2 The invited participants present at the seminar consisted of a prestigious group of basic scientists, neuropathologists, and medical and surgical neuro-oncologists. The meeting Chairmen, Glenn Dranoff (Boston, Mass.) and Darell Bigner (Durham, N.C.), began by defining two overall goals for the seminar. The first goal was to present and evaluate available data in the context of the following questions:1. To what degree will the immunologic privilege of the CNS limit a vaccination therapy?Neuro-

show abstract

Section: Antibody-based Vaccine Strategiesmentioning

confidence: 99%

THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif.

Sampson

1999

Neuro-Oncology

View full text Add to dashboard Cite

show abstract

“…In several rodent experimental tumor systems, suppression or prevention of tumor growth by administration of Ab2b has been demonstrated, even with target epitopes conventionally considered weakly immunogenic, such as gangliosides [7,12,18,31]. Most encouraging is the induction of cell-mediated responses following anti-id immunization in situations where immunization with antigen has been ineffective [32].…”

Section: Introductionmentioning

confidence: 99%

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

Wikstrand

Cole

Crotty

et al. 2002

Cancer Immunol Immunother

View full text Add to dashboard Cite

The use of anti-idiotype (anti-id) vaccines for immunotherapy of human cancers is attractive, as immunization with true anti-id reagents (Ab2 beta) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, or when a state of anergy to the self-expressed tumor-associated antigen exists. The aim of this study was to investigate the potential of an anti-id vaccine approach to the glioma-associated antigen epidermal growth factor receptor variant III (EGFRvIII) for human clinical trials. By using conventional methodology, seven rat mAbs specific for the binding site of the murine anti-EGFRvIII-specific mAb Y10, as defined by the ability to inhibit the binding of mAb Y10 to EGFRvIII expressed on cells or as purified protein, were generated, and a subset (3/7) was found to be true Ab2 beta, as defined by the ability to induce the formation of antibody directed against EGFRvIII in two species (mouse and rabbit) when used as immunogen. The ability of these three Ab2 beta to elicit a protective anti-tumor response when used as a vaccine in the syngeneic, subcutaneous C57Bl/6-B16mseEGFRvIII tumor model was investigated. Following vaccination with one Ab2 beta mAb (2C7), 6/20 mice failed to develop tumor upon challenge, and 3/20 mice with outgrowing tumors exhibited dramatic regression of incipient tumors. Vaccination with a second mAb (5G8) resulted in one tumor-free survivor and one tumor regressor; vaccination with the third Ab2 beta mAb (7D3) did not confer protection, but did significantly increase the latency period until tumor outgrowth in all vaccinated recipients. The ability of Ab2 beta mAb 2C7 to induce an anti-EGFRvIII response in non-human primates was investigated by using the saponin adjuvant approved for human clinical trial, QS-21. Three of three macaques produced anti-EGFRvIII titers, as detected on EGFRvIII-expressing cells by both ELISA and fluorescence-activated cytometric analysis, following six immunizations with Ab2 beta mAb 2C7 and QS-21. The results obtained confirm that an anti-id response in the EGFRvIII antigen system can be induced in rodents, rabbits, and non-human primates, and it may prove a useful adjunct to immunotherapeutic approaches to EGFRvIII-positive gliomas, breast carcinomas, and non-small-cell lung tumors.

show abstract

Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733

Maruyama

Benden

et al. 1996

Int. J. Cancer

View full text Add to dashboard Cite

Anti-idiotypic antibodies (Ab2) that bind to the antigencombining region of anti-tumor antibodies (Ab I) may functionally, and even structurally, mimic tumor antigen. We have previously demonstrated that polyclonal goat Ab2 directed against anti-human gastrointestinal carcinoma Ab I GA733 induces anti-anti-idiotypic antibodies (Ab3) in animals that are Ab I -like in their binding specificity and idiotope expression. To obtain more defined Ab2 vaccines with potentially increased specificity and efficacy, a monoclonal Ab2 (FG I) was produced against Ab I GA733 in rats. The monoclonal Ab2 FG I, similar to the polyclonal Ab2 described previously, induced Ab3 in rabbits that were Ab I -like in their idiotope expression and binding specificity to tumor cells and antigen. Antigen-specific Ab3 induced by Ab2 FG I were easily detected in unprocessed rabbit sera, whereas the demonstration of such Ab3 after polyclonal Ab2 immunization required purification of the Ab3 from the rabbit sera. In addition, Ab2 FG I induced antigen-specific humoral and cellular immunity in mice. Murine Ab3 bound specifically to antigen-positive tumor cells. Ab2-immunized mice showed antigen-specific delayed-type hypersensitivity (DTH) reaction, and cultured splenocytes from the immune mice demonstrated specific proliferation and cytokine (interferon-y and interleukin-4) secretion upon stimulation with GA733 antigen. However, immune mice were not protected against a challenge with syngeneic GA733 antigen-expressing colon carcinoma cells.o 1996 Wiley-Liss, Inc.

show abstract

Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody.

Cited by 60 publications

References 0 publications

THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif.

THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif.

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733

Contact Info

Product

Resources

About